Company Profile

NGM Biopharmaceuticals Stock Price, News & Analysis

Ticker:
NGM
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Why the stock is moving

Current closing-price context is not available for NGM.

Company overview

Business overview

NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs. Its business has been shaped by a broad platform approach and ongoing portfolio decisions.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, NGM sits in specialty biotechnology.

Business Model Characteristics

The company depends on pipeline prioritization, clinical data, and the ability to create value from a broad discovery engine.

Position Within the Biotechnology Landscape

NGM is a platform biotech name whose valuation depends on the quality of its selected programs.

Future catalysts

NGM is now largely a legacy and strategic-closeout story, so the catalysts are any asset monetization, wind-down, or portfolio-simplification update. The market is mainly waiting for clarity on the remaining corporate value.

Recent news

The five most recent related feed items are shown below in reverse chronological order.

  1. 01
  2. 02

    Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

    LEGN · Source: Legend Biotech Corporation

  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What does NGM Biopharmaceuticals do?

NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs. Its business has been shaped by a broad platform approach and ongoing portfolio decisions.

On which exchange is NGM stock listed?

NGM Biopharmaceuticals (NGM) is associated with NASDAQ, United States, Biopharma.

What is Biopharmaceuticals?

NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs.

Which conditions is NGM Biopharmaceuticals targeting with Biopharmaceuticals?

NGM Biopharmaceuticals is associated with oncology, metabolic disease based on its company overview and current catalyst commentary.

How does NGM Biopharmaceuticals describe recent progress with Biopharmaceuticals?

NGM is now largely a legacy and strategic-closeout story, so the catalysts are any asset monetization, wind-down, or portfolio-simplification update. The market is mainly waiting for clarity on the remaining corporate value.

What future catalysts are investors watching for NGM Biopharmaceuticals?

NGM is now largely a legacy and strategic-closeout story, so the catalysts are any asset monetization, wind-down, or portfolio-simplification update. The market is mainly waiting for clarity on the remaining corporate value.